Published in Int Immunol on December 27, 2004
T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer (2005) 1.08
Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res (2013) 0.92
Expression of CD200 on AML blasts directly suppresses memory T-cell function. Leukemia (2012) 0.86
T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer. Clin Vaccine Immunol (2010) 0.79
Progress in the development of a cervical cancer vaccine. Ther Clin Risk Manag (2006) 0.78
Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine. PLoS One (2015) 0.75
CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modification. Immunology (2014) 0.75
Surveillance of HIV risk and prevention behaviors of men who have sex with men--a national application of venue-based, time-space sampling. Public Health Rep (2007) 4.78
The nature of telomere fusion and a definition of the critical telomere length in human cells. Genes Dev (2007) 1.88
HIV behavioral surveillance in the U.S.: a conceptual framework. Public Health Rep (2007) 1.87
Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis (2005) 1.68
Summary of Notifiable Diseases - United States, 2011. MMWR Morb Mortal Wkly Rep (2013) 1.53
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51
Hepatitis B testing and vaccination among Vietnamese- and Cambodian-Americans. J Community Health (2009) 1.46
Mumps outbreak in Orthodox Jewish communities in the United States. N Engl J Med (2012) 1.40
Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin Cancer Res (2011) 1.25
Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol (2002) 1.18
Identification of human papillomavirus type 58 lineages and the distribution worldwide. J Infect Dis (2011) 1.13
Framing patient consent for student involvement in pelvic examination: a dual model of autonomy. J Med Ethics (2013) 1.06
HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. Int J Cancer (2013) 1.05
Factors associated with recent sildenafil (viagra) use among men who have sex with men in the United States. J Acquir Immune Defic Syndr (2006) 1.02
Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women. J Gen Virol (2007) 0.97
Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood (2004) 0.93
Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol (2005) 0.92
Human Papillomavirus genotype testing combined with cytology as a 'test of cure' post treatment: the importance of a persistent viral infection. J Clin Virol (2011) 0.92
T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother (2005) 0.91
Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations. Int J Cancer (2012) 0.91
Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in the UK. BMC Public Health (2013) 0.89
Human papillomavirus, cervical carcinogenesis and chemoprevention with Indole derivates - a review of pathomechanisms. Mol Nutr Food Res (2008) 0.86
A novel tumor antigen derived from enhanced degradation of bax protein in human cancers. Cancer Res (2011) 0.85
Environmental factors potentially associated with mumps transmission in yeshivas during a mumps outbreak among highly vaccinated students: Brooklyn, New York, 2009-2010. Hum Vaccin Immunother (2013) 0.85
Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica (2013) 0.85
Evaluation of the new National HIV Behavioral Surveillance System (NHBS) is imperative. Sex Transm Dis (2006) 0.84
The potential impact of human papillomavirus vaccination in contemporary cytologically screened populations may be underestimated: an observational retrospective analysis of invasive cervical cancers. Int J Cancer (2009) 0.84
The risk of cervical cancer associated with specific types of human papillomavirus: a case-control study in a UK population. Int J Cancer (2010) 0.84
Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. Int J Cancer (2006) 0.84
Activated B cells mediate efficient expansion of rare antigen-specific T cells. Hum Immunol (2007) 0.83
Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted HLA class I/peptide complexes in SCID mice. Int J Cancer (2002) 0.83
Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. Int J Cancer (2005) 0.82
Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy. Cancer Immunol Immunother (2013) 0.81
Human papillomavirus infection is rare in nonmalignant tonsil tissue in the UK: implications for tonsil cancer precursor lesions. Int J Cancer (2014) 0.79
Human papillomavirus type distribution in vulval intraepithelial neoplasia determined using PapilloCheck DNA Microarray. J Med Virol (2011) 0.79
T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer. Clin Vaccine Immunol (2010) 0.79
T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer. J Med Virol (2011) 0.79
HPV16 E6 29-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function. Int J Cancer (2008) 0.79
Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. Public Health Rep (2012) 0.78
Single negative colposcopy: is it enough to rule out high-grade disease? J Med Screen (2011) 0.77
mRNA sequencing of novel cell lines from human papillomavirus type-16 related vulval intraepithelial neoplasia: consequences of expression of HPV16 E4 and E5. J Med Virol (2014) 0.77
Promiscuous behavior of HPV16E6 specific T cell receptor beta chains hampers functional expression in TCR transgenic T cells, which can be restored in part by genetic modification. Cell Oncol (2010) 0.76
CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modification. Immunology (2014) 0.75